China's CStone Pharmaceuticals Co. Ltd. completed a $260 million series B financing.
The funding was led by Singapore sovereign wealth fund GIC Pvt. Ltd. with participation from new investors including Sequoia China, Yunfeng Capital and 6 Dimensions Capital among others.
CStone previously raised $150 million in its series A financing in 2016.
The Chinese biopharmaceutical company plans to use the proceeds to develop its anti-PD-L1 experimental drug, CS1001, and for the expansion of its pipeline.
CS1001 is part of a class of immune system-boosting drugs called checkpoint inhibitors. Inhibitor drugs target immune checkpoints such as PD-L1 and CTLA-4 to prevent cancer cells from downregulating and hiding from the body's immune system.